- Home
- IDYA
as 07-26-2024 4:00pm EST
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, an inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 3.4B | IPO Year: | 2019 |
| Target Price: | $54.55 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.01 | EPS Growth: | N/A |
| 52 Week Low/High: | $21.12 - $47.74 | Next Earning Date: | 08-08-2024 |
| Revenue: | $15,504,000 | Revenue Growth: | -67.33% |
| Revenue Growth (this year): | -41.86% | Revenue Growth (next year): | 30.47% |
Stock Insider Trading Activity of IDEAYA Biosciences Inc. (IDYA)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| WHITE MICHAEL ANTHONY | IDYA | Chief Scientific Officer | May 29 '24 | Sell | $36.23 | 27,649 | $1,001,587.79 | 851 | SEC Form 4 |
| WHITE MICHAEL ANTHONY | IDYA | Chief Scientific Officer | May 29 '24 | Sell | $36.78 | 851 | $31,296.63 | 0 | SEC Form 4 |
| Hata Yujiro S | IDYA | President and CEO | May 14 '24 | Sell | $41.60 | 54,408 | $2,263,432.65 | 680,190 | SEC Form 4 |
| Hata Yujiro S | IDYA | President and CEO | May 14 '24 | Sell | $41.84 | 2,303 | $96,347.62 | 677,887 | SEC Form 4 |
| Hata Yujiro S | IDYA | President and CEO | May 14 '24 | Sell | $42.57 | 53,592 | $2,281,631.17 | 708,151 | SEC Form 4 |
| Hata Yujiro S | IDYA | President and CEO | May 14 '24 | Sell | $43.48 | 29,761 | $1,293,933.88 | 678,390 | SEC Form 4 |
| Hata Yujiro S | IDYA | President and CEO | May 14 '24 | Sell | $44.12 | 503 | $22,191.30 | 677,887 | SEC Form 4 |
| Hata Yujiro S | IDYA | President and CEO | May 14 '24 | Sell | $41.73 | 30,084 | $1,255,504.60 | 682,236 | SEC Form 4 |
| Hata Yujiro S | IDYA | President and CEO | May 14 '24 | Sell | $42.37 | 4,349 | $184,249.73 | 677,887 | SEC Form 4 |
| Ruiz Briseno Andres | IDYA | See Remarks | Feb 9 '24 | Sell | $46.02 | 2,000 | $92,044.60 | 24,531 | SEC Form 4 |
| Hata Yujiro S | IDYA | President and CEO | Feb 8 '24 | Sell | $45.15 | 75,815 | $3,422,834.97 | 677,887 | SEC Form 4 |
| Hata Yujiro S | IDYA | President and CEO | Feb 8 '24 | Sell | $45.54 | 23,557 | $1,072,715.11 | 677,887 | SEC Form 4 |
| Hata Yujiro S | IDYA | President and CEO | Feb 1 '24 | Sell | $45.00 | 624 | $28,080.00 | 677,891 | SEC Form 4 |
| Hata Yujiro S | IDYA | President and CEO | Feb 1 '24 | Sell | $45.01 | 4 | $180.04 | 677,887 | SEC Form 4 |
| Ruiz Briseno Andres | IDYA | See Remarks | Jan 22 '24 | Sell | $42.03 | 2,000 | $84,050.20 | 26,531 | SEC Form 4 |
| Ruiz Briseno Andres | IDYA | See Remarks | Jan 12 '24 | Sell | $38.01 | 2,000 | $76,025.60 | 28,531 | SEC Form 4 |
| Hata Yujiro S | IDYA | President and CEO | Jan 12 '24 | Sell | $40.04 | 12,261 | $490,913.27 | 677,887 | SEC Form 4 |
| Hata Yujiro S | IDYA | President and CEO | Jan 12 '24 | Sell | $40.17 | 62,739 | $2,519,968.40 | 677,887 | SEC Form 4 |
| Hata Yujiro S | IDYA | President and CEO | Dec 15 '23 | Sell | $35.03 | 75,000 | $2,627,617.50 | 677,887 | SEC Form 4 |
| Throne Jason | IDYA | Chief Legal Officer | Dec 15 '23 | Sell | $35.04 | 10,000 | $350,371.00 | 0 | SEC Form 4 |
| Ruiz Briseno Andres | IDYA | See Remarks | Dec 14 '23 | Sell | $34.00 | 1,672 | $56,848.00 | 30,859 | SEC Form 4 |
| Ruiz Briseno Andres | IDYA | See Remarks | Dec 14 '23 | Sell | $34.01 | 328 | $11,153.64 | 30,531 | SEC Form 4 |
| Throne Jason | IDYA | Chief Legal Officer | Nov 3 '23 | Sell | $30.09 | 5,163 | $155,359.83 | 0 | SEC Form 4 |
Latest IDEAYA Biosciences Inc. News
IDYA Breaking Stock News: Dive into IDYA Ticker-Specific Updates for Smart Investing
Zacks
3 days ago
How Much Upside is Left in IDEAYA Biosciences (IDYA)? Wall Street Analysts Think 32.97%
MT Newswires
10 days ago
Wedbush Cuts Price Target on IDEAYA Biosciences to $54 From $56, Maintains Outperform Rating
Simply Wall St.
12 days ago
Industry Analysts Just Made A Meaningful Upgrade To Their IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Revenue Forecasts
MT Newswires
14 days ago
JPMorgan Raises Price Target on IDEAYA Biosciences to $69 From $65, Maintains Overweight Rating
PR Newswire
15 days ago
IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Zacks
15 days ago
Biotech Stock Roundup: KYMR, IDYA, QURE Soar on Study Data, HLVX Tanks on Study Failure
MT Newswires
16 days ago
RBC Raises Price Target on IDEAYA Biosciences to $61 From $53, Keeps Outperform, Speculative Risk
MT Newswires
17 days ago
IDEAYA Biosciences Prices $263 Million Public Offering
Compare IDYA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IDYA IDEAYA Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.